Recent Updates
Recently added Catalysts

GI148512

Phase 3

Acne Vulgaris | Small molecule | Dermatology |GSK plc|Last Updated: Aug 5, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment360
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01400932Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese SubjectsPHASE3 COMPLETED 360Jul 1, 2011Apr 1, 2012Aug 5, 201419 Japan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Absolute Change in Total Lesion Counts From Baseline to Week 12
Baseline and Week 12

The investigator (or subinvestigator) counted all inflammatory lesions (papules, pustules, and nodular lesions) and non-inflammatory lesions (open and closed comedos; diagnosis based on palpation) on the face at each study visit. An open comedo is an open, widely dilated follicle with black-colored sebum, due to melanin and oxidation, and keratinous material that forms a plug, thereby obstructing the pilosebaceous duct. A closed comedo is a closed follicle filled with impacted sebum covered by keratin that has a whitish color. A papule is a small, raised, red, dome-shaped palpable lesion. A pustule is a raised, dome-shaped palpable lesion containing yellow fluid (pus). A nodule may be a raised or deep-seated, dome-shaped palpable lesion of at least 5 millimeters in diameter.

Secondary Endpoints
Absolute Change in Total Lesion Counts From Baseline to Weeks 1, 2, 4, and 8
Baseline; Weeks 1, 2, 4, and 8
Absolute Change From Baseline in Inflammatory Lesion (IL) Count and Non-inflammatory Lesion (NIL) Count to Weeks 1, 2, 4, 8, and 12
Baseline; Weeks 1, 2, 4, 8, and 12
Percent Change From Baseline in Total, Inflammatory, and Non-inflammatory Lesion Counts to Weeks 1, 2, 4, 8, and 12
Baseline; Weeks 1, 2, 4 and 8 and 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
GI148512 (Benzoyl Peroxide 3% Gel)EXPERIMENTALSubjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime. Comparison of 2 arms (GI148512 vs vehicle)
vehicle gelPLACEBO_COMPARATORSubjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
Interventions
NameTypeDescription
GI148512DRUGGI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
vehicle gelDRUGMatching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — 45 Years
SexALL
Healthy VolunteersNo
Study Sites19

Inclusion Criteria: * Male or female subjects 12 to 45 years (inclusive) of age in good general health. * Subjects must have both on the face: A) A minimum of 17 but not more than 60 inflammatory lesions (papules / pustules), including nasal lesions. And B) A minimum of 20 but not more than 150 n...

Countries:Japan
Unlock Eligibility Criteria